{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:44:52Z","timestamp":1791009892017,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.coph.2013.03.015","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T11:31:48Z","timestamp":1366284708000},"page":"377-385","source":"Crossref","is-referenced-by-count":82,"title":["Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"13","author":[{"given":"Hillary","family":"Loomis-King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany B","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2013.03.015_bib0005","article-title":"Molecular mechanisms in progressive idiopathic pulmonary fibrosis","volume":"27","author":"Steele","year":"2012","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.coph.2013.03.015_sbref0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","author":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1164\/ajrccm.164.7.2003140","article-title":"Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model","volume":"164","author":"King","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1183\/09059180.00001012","article-title":"Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis","volume":"21","author":"Gunther","year":"2012","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.coph.2013.03.015_bib0030","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1172\/JCI60323","article-title":"Pulmonary fibrosis: patterns and perpetrators","volume":"122","author":"Noble","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2013.03.015_bib0035","first-page":"517","article-title":"EMT and interstitial lung disease: a mysterious relationship","volume":"18","author":"Kage","year":"2012","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/1753465810379801","article-title":"The pathogenesis of idiopathic pulmonary fibrosis","volume":"4","author":"Coward","year":"2010","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.coph.2013.03.015_bib0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0002-9440(10)62289-4","article-title":"CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury","volume":"166","author":"Moore","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2013.03.015_bib0050","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1165\/rcmb.2005-0239OC","article-title":"The role of CCL12 in the recruitment of fibrocytes and lung fibrosis","volume":"35","author":"Moore","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0055","doi-asserted-by":"crossref","first-page":"L510","DOI":"10.1152\/ajplung.00122.2011","article-title":"Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis","volume":"301","author":"Redente","year":"2011","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.coph.2013.03.015_bib0060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/gerona\/glr211","article-title":"Pulmonary fibrosis induced by gamma-herpesvirus in aged mice is associated with increased fibroblast responsiveness to transforming growth factor-beta","volume":"67","author":"Naik","year":"2012","journal-title":"J Gerontol A: Biol Sci Med Sci"},{"key":"10.1016\/j.coph.2013.03.015_bib0065","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1165\/rcmb.2011-0224OC","article-title":"Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis","volume":"46","author":"Torres-Gonzalez","year":"2012","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0070","first-page":"241","article-title":"Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis","volume":"4","author":"Englert","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.coph.2013.03.015_bib0075","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1513\/pats.200601-001TK","article-title":"Evolving concepts of apoptosis in idiopathic pulmonary fibrosis","volume":"3","author":"Thannickal","year":"2006","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.coph.2013.03.015_bib0080","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1083\/jcb.201004082","article-title":"Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression","volume":"190","author":"Liu","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0085","doi-asserted-by":"crossref","first-page":"13294","DOI":"10.1074\/jbc.M109.088864","article-title":"Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase","volume":"285","author":"Maruhashi","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2013.03.015_sbref0090","first-page":"5","article-title":"Periostin promotes fibrosis and predicts progression in patients with Idiopathic Pulmonary Fibrosis","volume":"5","author":"Naik","year":"2012","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.coph.2013.03.015_sbref0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1183\/09031936.00059810","article-title":"Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias","volume":"37","author":"Okamoto","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2013.03.015_bib0100","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/ars.2007.1897","article-title":"The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis","volume":"10","author":"Bringardner","year":"2008","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.coph.2013.03.015_bib0105","doi-asserted-by":"crossref","first-page":"e9683","DOI":"10.1371\/journal.pone.0009683","article-title":"Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages","volume":"5","author":"Murray","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coph.2013.03.015_sbref0110","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_sbref0115","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0120","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/ajrccm.161.2.ats3-00","article-title":"Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)","volume":"161","author":"American Thoracic Society","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1164\/ajrccm\/144.2.291","article-title":"Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial","volume":"144","author":"Raghu","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.coph.2013.03.015_bib0130","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1378\/chest.125.6.2169","article-title":"Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis","volume":"125","author":"Collard","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.coph.2013.03.015_bib0135","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMoa042976","article-title":"High-dose acetylcysteine in idiopathic pulmonary fibrosis","volume":"353","author":"Demedts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.03.015_sbref0140","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0145","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1517\/14712598.6.10.1051","article-title":"Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis","volume":"6","author":"Bouros","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coph.2013.03.015_bib0150","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM199910213411703","article-title":"A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis","volume":"341","author":"Ziesche","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0155","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa030511","article-title":"A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis","volume":"350","author":"Raghu","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0160","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2013.03.015_bib0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2009-0388TR","article-title":"Endothelin in pulmonary fibrosis","volume":"44","author":"Fonseca","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.200705-732OC","article-title":"BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"177","author":"King","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0180","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1289\/ehp.00108s4751","article-title":"Interstitial fibrosis and growth factors","volume":"108","author":"Lasky","year":"2000","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.coph.2013.03.015_bib0185","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","article-title":"Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial","volume":"178","author":"Raghu","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0190","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coph.2013.03.015_bib0195","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0200","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0041-1345(96)00325-9","article-title":"Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo","volume":"29","author":"Nair","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1016\/j.coph.2013.03.015_bib0205","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1183\/09031936.02.00281602","article-title":"The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats","volume":"19","author":"Simler","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2013.03.015_bib0210","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1440-1843.2011.01955.x","article-title":"An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis","volume":"16","author":"Malouf","year":"2011","journal-title":"Respirology"},{"key":"10.1016\/j.coph.2013.03.015_bib0215","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0168-8278(02)00245-3","article-title":"Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production","volume":"37","author":"Di Sario","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.coph.2013.03.015_bib0220","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0225","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coph.2013.03.015_sbref0230","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2013.03.015_bib0235","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/2049-6958-7-41","article-title":"Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?","volume":"7","author":"Antoniu","year":"2012","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0240","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.biocel.2008.02.016","article-title":"Hyper-responsiveness of IPF\/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2","volume":"40","author":"Murray","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0245","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.27382","article-title":"Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis","volume":"62","author":"Sonnylal","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2013.03.015_sbref0250","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4236\/abb.2012.326085","article-title":"Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts","volume":"3","author":"Sisson","year":"2012","journal-title":"Adv Biosci Biotechnol"},{"key":"10.1016\/j.coph.2013.03.015_bib0255","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1165\/rcmb.2011-0025RT","article-title":"Prostaglandin E2 and the pathogenesis of pulmonary fibrosis","volume":"45","author":"Bozyk","year":"2011","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.coph.2012.02.016","article-title":"Selective PDE inhibitors as novel treatments for respiratory diseases","volume":"12","author":"Page","year":"2012","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.coph.2013.03.015_bib0265","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1016\/j.bmcl.2011.03.068","article-title":"Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin","volume":"21","author":"Jiang","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.coph.2013.03.015_bib0270","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.30262","article-title":"Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma","volume":"63","author":"Castelino","year":"1405","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coph.2013.03.015_bib0275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1189\/jlb.0112033","article-title":"FcgammaRI mediates serum amyloid P inhibition of fibrocyte differentiation","volume":"92","author":"Crawford","year":"2012","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.coph.2013.03.015_bib0280","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0167-5699(99)01469-3","article-title":"The chemokine system: redundancy for robust outputs","volume":"20","author":"Montovani","year":"1999","journal-title":"Immunol Today"},{"key":"10.1016\/j.coph.2013.03.015_bib0285","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(02)01758-2","article-title":"A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level","volume":"446","author":"Nakazato","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.coph.2013.03.015_bib0290","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2006-957331","article-title":"Inflammation and angiogenesis in fibrotic lung disease","volume":"27","author":"Keane","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0295","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2013.03.015_bib0300","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10555-005-5131-6","article-title":"Integrin-mediated activation of latent transforming growth factor beta","volume":"24","author":"Sheppard","year":"2005","journal-title":"Cancer Metastasis Rev"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489213000490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489213000490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T17:22:20Z","timestamp":1539710540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489213000490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1471489213000490"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2013.03.015","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}